SCHEMBL6314968

SCHEMBL6314968

O=c1[nH]c(=O)n(-c2ccccc2)c2nc(O)c(-c3ccccc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 6/20 0.46
MAPT P10636 4/20 0.41
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 4/20 0.41
CSNK2A1 P68400 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 3/20 0.40
TSHR P16473 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
ITGA4 P13612 2/20 0.39
ITGB7 P26010 2/20 0.39
GSK3B P49841 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5442836 0.85 TP53 (0.44) MAPTKDM4EKMT2AALDH1A1HPGD
SCHEMBL5437607 0.84 KDM4E (0.46) DHFRMAPTKDM4EKMT2ACSNK2A1
SCHEMBL5440039 0.80 PNP (0.52) MAPTKDM4EKMT2AALDH1A1HPGD
SCHEMBL5449115 0.80 MEN1 (0.45) KDM4EKMT2AALDH1A1HPGDMEN1
SCHEMBL5443537 0.74 ALDH1A1 (0.44) DHFRMAPTKDM4EKMT2ALMNA
SCHEMBL6320759 0.73 KDM4E (0.48) MAPTKDM4EKMT2ALMNAALDH1A1
SCHEMBL5446767 0.73 KMT2A (0.45) MAPTKDM4EKMT2ALMNAALDH1A1
SCHEMBL5446598 0.73 BRDT (0.41) KDM4EKMT2AALDH1A1SMN1; SMN2TSHR
SCHEMBL5443099 0.72 PGR (0.45) MAPTKMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL5448031 0.71 KDM4E (0.47) MAPTKDM4EKMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP claimed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP disclosed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 DHFR 100/4885MAPT 388/4885KDM4E 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.